← All trials
NCT05743946
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 18, 2023
- Primary completion
- Jun 30, 2024
- Completion date
- Jun 30, 2024
- First posted
- Feb 24, 2023
- Last posted
- Jun 5, 2023
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Emory UniversityLead sponsor
- Emory UniversityOverall official - principal investigator
- Emory UniversityReponsible party - principal investigator
- The Marcus FoundationCollaborator
- Emory UniversitySponsor investigator
- Emory UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.